Edition:
United States

Verastem Inc (VSTM.OQ)

VSTM.OQ on NASDAQ Stock Exchange Global Market

1.20USD
9 Dec 2016
Change (% chg)

$0.04 (+3.45%)
Prev Close
$1.16
Open
$1.15
Day's High
$1.20
Day's Low
$1.15
Volume
8,042
Avg. Vol
20,250
52-wk High
$2.05
52-wk Low
$1.05

Latest Key Developments (Source: Significant Developments)

Verastem reports Q2 loss per share $0.23
Monday, 8 Aug 2016 08:40am EDT 

Verastem Inc : Verastem reports second quarter 2016 financial results . Q2 loss per share $0.23 . Q2 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S .Expect to have sufficient cash, cash equivalents and short-term investments to fund research and development programs and operations into 2018.  Full Article

Verastem Q1 loss per share $0.22
Monday, 9 May 2016 04:05pm EDT 

Verastem Inc : Expect to have sufficient cash, cash equivalents,short-term investments to fund research and development programs and operations into 2018 . Verastem reports first quarter 2016 financial results . Q1 loss per share $0.22 .Q1 earnings per share view $-0.30 -- Thomson Reuters I/B/E/S.  Full Article

Verastem Announces Reduction of Workforce
Thursday, 8 Oct 2015 04:46pm EDT 

Verastem Inc:Says reduction of its workforce by approximately 50% to 20 full time employees.All affected employees will receive severance pay and outplacement assistance.As a result of the reduction in force and associated costs, Verastem estimates annual savings of about $4.9 million in cash operating expenses on a going forward basis, with estimated one-time severance and related costs of about $825,000 over Q4 2015 and the Q1 2016.  Full Article

Verastem receives Orphan Drug Designation from FDA for VS-5584 in Mesothelioma
Thursday, 12 Feb 2015 07:00am EST 

Verastem Inc:Says that VS-5584 has received orphan drug designation from the U.S. Food and Drug Administration for use in the treatment of mesothelioma.The designation was created to encourage the development of drugs that may provide significant benefit to patients suffering from rare diseases.Verastem recently initiated a Phase 1 clinical study evaluating the combination of VS-5584 and VS-6063 in patients with relapsed or progressive malignant pleural mesothelioma.The combination clinical trial is supported by preclinical work demonstrating the synergistic activity of VS‐6063 and VS‐5584 in mesothelioma models in vitro and in vivo.VS-5584 is also being evaluated in a Phase 1 study in advanced solid tumors where the compound has been generally well tolerated and preliminary activity has been observed, including in mesothelioma.Some patients have been on study for over 6 months and the maximum tolerated dose of VS-5584 has not been reached.  Full Article

Verastem Inc closes of public offering of common stock
Thursday, 29 Jan 2015 07:00am EST 

Verastem Inc:Says the closing of the previously announced public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,087,500 shares of common stock, at the public offering price of $6.50 per share.The exercise of the underwriters' option brought the total number of shares of common stock sold by Verastem to 8,337,500 shares and increased the total gross proceeds raised in this offering to $54.2 million, before deducting the underwriting discounts and commissions.The net proceeds to Verastem from this offering were $50.9 million.  Full Article

Verastem Inc announces pricing of public offering of common stock
Thursday, 22 Jan 2015 08:43pm EST 

Verastem Inc:Announced the pricing of its previously announced underwritten public offering of 7,250,000 shares of its common stock, offered at a price of $6.50 per share to the public.The net proceeds to Verastem from this offering are expected to be about $44.1 million, after deducting underwriting discounts and commissions and offering expenses.All of the shares sold in the offering will be sold by Verastem.The offering is expected to close on or about Jan. 28, 2015.Verastem has granted to the underwriters a 30-day option to purchase up to 1,087,500 additional shares of common stock.Verastem anticipates using the net proceeds from the offering for its registration-directed COMMAND study in mesothelioma and the initiation of associated studies in preparation for a possible NDA filing to the FDA and similar filings to other regulatory authorities.Jefferies LLC and Leerink Partners LLC are acting as joint book-running managers and Guggenheim Securities, LLC and Oppenheimer & Co. Inc. are acting as co-lead managers in the offering.  Full Article

Verastem Inc announces proposed public offering of common stock
Tuesday, 20 Jan 2015 04:01pm EST 

Verastem Inc:Intends to offer and sell $40 mln of its common stock in an underwritten public offering.Offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.All of the shares to be sold in the offering are to be sold by Verastem.Jefferies LLC and Leerink Partners LLC are acting as joint book-running managers and Guggenheim Securities, LLC and Oppenheimer & Co. Inc. are acting as co-lead managers in the offering.  Full Article

Verastem receives orphan medicinal product designation from European Commission for VS-5584 in Mesothelioma
Tuesday, 20 Jan 2015 08:00am EST 

Verastem Inc:Receives orphan medicinal product designation from the European Commission for use in mesothelioma.Designation was created to encourage the development of drugs that may provide benefit to patients suffering from rare diseases.Verastem`s VS-5584, a dual mTORC1/2 and PI3K inhibitor, is currently being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors and a Phase 1 combination study with VS-6063 in patients with relapsed malignant pleural mesothelioma.  Full Article

Verastem doses first patient in Phase 1 clinical trial
Tuesday, 20 Jan 2015 07:00am EST 

Verastem Inc:Says dosing of the first patient in a new clinical trial evaluating the combination of VS-5584, its dual mTORC1/2 and PI3K inhibitor, in combination with VS-6063, the company's lead focal adhesion kinase (FAK) inhibitor, in patients with relapsed mesothelioma.The Phase 1 open-label, dose escalation and schedule finding study is designed to assess safety, pharmacokinetics, pharmacodynamics and initial observations of clinical activity.The study is expected to enroll up to 56 patients at clinical sites in the UK and US.  Full Article

BRIEF-Verastem reports Q3 loss per share $0.21

* Q3 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage: